PLN774.6m market cap
PLN48.5 last close
Ryvu Therapeutics is an oncology R&D company. The two most advanced assets in clinical development are SEL24, a dual PIM/FLT3 inhibitor out-licensed to Menarini Group, and wholly owned SEL120, a selective CDK8 inhibitor. Ryvu also has a diversified preclinical R&D pipeline.
Investment summary
Selvita has split into two separate companies. Selvita will continue trading as Ryvu Therapeutics, a newly introduced brand, and will fully focus on innovative drug discovery and development. Selvita CRO, drug discovery services, was spun out into a separate listed entity. We believe both businesses have sufficient momentum to sustain the split. Ryvu Therapeutics R&D pipeline is progressing according to plan and two clinical trials with SEL24 and SEL120 could deliver data over 2019–20. The lead product is SEL120, a CDK8 inhibitor, partnered with the Leukemia & Lymphoma Society for AML. SEL120 is being explored in a Phase Ib trial in AML and HR-MDS with the first patient recruited in September 2019. SEL24 is a dual PIM/FLT3 inhibitor in Phase I/II for AML out-licensed to Menarini in March 2017.
Industry outlook
The profiles of SEL24 and SEL120 are potentially unique compared to existing clinical-stage competitors and both candidates may offer efficacy advantages.
Last updated on 18/10/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (PLNm) | 98.1 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Paweł Przewięźlikowski | CEO |
| Bogusław Sieczkowski | COO |
| Tomasz Nocun | IR |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma